Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00183937 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

StatusTerminated
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Completed to Terminatedv10 Show 4 more changesShow less
    • Results first posted: May 15, 2026
    • Primary endpoint revised
    • Sponsor's reason: Sponsor stopped study early.
    • Secondary endpoints: 1 to 3
  2. Primary completion date: Oct 2010 to Oct 23, 2010
    • Study completion date: Dec 2011 to Jun 11, 2012
    • Start date: Apr 2005 to Apr 30, 2005
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Trial status: Active, Not Recruiting to Completedv7 Show 4 more changesShow less
    • Enrollment target: estimated 37 to confirmed 15
    • Primary completion date: Jun 2010 to Oct 2010
    • Study completion date changed from estimate of Dec 2012 to Dec 2011
    • Study arms: 0 to 1
  5. Primary completion date: Oct 2009 to Jun 2010v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date changed from estimate of Dec 2011 to Oct 2009v5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: 37
    • Primary completion date: Dec 2011
    • Study completion date: Dec 2012
    v3
  4. Trial status: Recruiting to Suspended
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment. PS 341 is a type of drug known as a "proteasome inhibitor." By inhibiting the "proteasome" in cancer cells, PS-341 alters the way those cells divide). We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests (prostate specific antigen, also called PSA), and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer.
Trial Details
NCT Number NCT00183937
Lead Sponsor University of Southern California
Collaborators: Millennium Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov